Bimosiamose
Bimosiamose had been in phase II clinical trials for the treatment of asthma, chronic obstructive pulmonary disease (COPD), plaque psoriasis and atopic dermatitis.
This compound was originally discovered by Encysive Pharmaceuticals (acquired by Pfizer in 2008), then licensed to Revotar Biopharmaceuticals AG for codevelopment in 2000. However, no recent development has been reported.
General Information
Update Date：2016-02-04
- Drug Name：
- Bimosiamose
- Research Code：
- TBC-1269
- Trade Name：
- MOA：
- L/E/P-selectin antagonist
- Indication：
- Asthma; Chronic obstructive pulmonary disease (COPD); Plaque psoriasis; Atopic dermatitis
- Status：
- Phase II (Pending)
- Company：
- Encysive (Originator) , Revotar
- Sales：
- ATC Code：
Chemical Structure
Update Date：2016-02-04
|
Molecular Weight | 862.91 | ||||||||||||
| Formula | C46H54O16 | |||||||||||||
| CAS No. | 187269-40-5 (Bimosiamose); | |||||||||||||
| Chemical Name | [1,1'-Biphenyl]-3-acetic acid, 3',3'''-(1,6-hexanediyl)bis[6'-(a-D-mannopyranosyloxy)- | |||||||||||||
| Bimosiamose （Free Acid/Base）Parameters： | ||||||||||||||
|
||||||||||||||
| *：Calculated by ACD/Labs software V11.02. | ||||||||||||||